Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 120 EUR 0.5% Market Closed
Market Cap: 10.1B EUR

Net Margin
Ipsen SA

11.9%
Current
17%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.9%
=
Net Income
447.9m
/
Revenue
3.8B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
FR
Ipsen SA
PAR:IPN
9.9B EUR
12%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
500.8B USD
27%
CH
Roche Holding AG
SIX:ROG
262B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
213.4B GBP
16%
CH
Novartis AG
SIX:NOVN
211.1B CHF
26%
US
Merck & Co Inc
NYSE:MRK
265.9B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
212.8B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.3B USD
16%
No Stocks Found

Ipsen SA
Glance View

Market Cap
9.9B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
147 EUR
Undervaluation 18%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
11.9%
=
Net Income
447.9m
/
Revenue
3.8B
What is the Net Margin of Ipsen SA?

Based on Ipsen SA's most recent financial statements, the company has Net Margin of 11.9%.

Back to Top